Barzolvolimab Phase 3 CSU Win: Regulatory Path Clear, Commercial Case Unproven

Celldex's Barzolvolimab Achieves Positive Phase 3 Results in CSU

Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. Both trials met their primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints, demonstrating clinically meaningful and statistically significant improvements in disease activity. Barzolvolimab was well-tolerated through the 24-week placebo-controlled treatment period with a favorable safety profile. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027.

• The Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies demonstrated rapid, profound, and sustained efficacy, meeting the primary endpoint (mean change from baseline in UAS7 at Week 12) and all key secondary endpoints with high statistical significance (p<.00001 for both doses in both studies for primary endpoint). Efficacy was sustained or deepened from weeks 12 to 24, consistent with prior Phase 2 experience.
• Barzolvolimab showed significantly higher complete response rates (UAS7=0) compared to placebo at Weeks 12 and 24 (e.g., 42.4% vs 9.3% for 150 mg Q4W at Week 12 in EMBARQ-CSU1). It also demonstrated strong differentiation in omalizumab-refractory CSU patients and those with severe disease or angioedema, with a higher proportion achieving complete resolution of angioedema (AAS7=0).
• The drug was well-tolerated with a favorable safety profile through 24 weeks, consistent with prior Phase 2 experience. Treatment will continue to 52 weeks in both trials, and Celldex anticipates submitting a Biologics License Application (BLA) to the FDA in 2027, positioning barzolvolimab as a potential transformational therapy for CSU patients.

Barzolvolimab Delivers Unprecedented Efficacy and Favorable Safety in CSU

Several recent studies have advanced the understanding of treatment options in chronic spontaneous urticaria (CSU) across a range of mechanisms. A prospective randomized non-blinded comparative trial evaluated bilastine up-dosing (40 mg, administered as 20 mg twice daily) versus a combination of bilastine 20 mg and levocetirizine 5 mg in 62 patients over 6 weeks. Both groups demonstrated statistically significant improvement in UAS7 scores (p <0.05) at week 6. Group A, receiving bilastine up-dosing, showed a reduction in UAS7 from 19.4% to 0.03% with minimal side effects, leading investigators to conclude that bilastine up-dosing was efficient, secure, and well tolerated relative to the combination regimen. Separately, a phase 2a open-label proof-of-concept study of lirentelimab — an anti-sialic acid-binding immunoglobulin-like lectin 8 monoclonal antibody — enrolled 45 patients with antihistamine-refractory chronic urticaria across four cohorts. In omalizumab-naive CSU patients, the mean UAS7 change at week 22 was -73%, with a complete response rate (Urticaria Control Test score ≥12) of 92%. In omalizumab-refractory CSU patients, the mean UAS7 change was -47%, with a complete response rate of 36%. The most common adverse events were infusion-related reactions (43%; all mild/moderate and transient), nasopharyngitis (21%), and headache (19%), with no treatment-related serious adverse events reported.

A retrospective, single-center, observational cohort study assessed domestic omalizumab (Enyitan®, 300 mg every 4 weeks) in 71 elderly CSU patients (aged ≥65 years) with moderate-to-severe disease over 24 weeks. Of the 62 patients completing the study, 88.7% achieved well-controlled disease (UAS7 ≤6) at week 24. UCT scores improved from 5.2±2.1 to 14.8±3.2, and DLQI scores decreased from 15.6±4.3 to 3.1±2.8 (both p<0.001). Treatment was well tolerated, with only mild, transient adverse events reported, predominantly injection-site reactions (9.7%) and headache (3.2%). Additionally, a small retrospective study examined low-dose interleukin-2 (1.0 million international units daily for 7 consecutive days, administered intramuscularly) in 15 CSU patients refractory to H-antihistamines. At week 12, 73.3% of patients achieved complete response, with a mean UAS7 change from baseline of -16.9 (95% CI, -24.0 to -9.8) and a mean UCT change of 6.6 (95% CI, 4.2 to 8.9). Local injection-site reactions were the most common adverse events, and no serious adverse events were reported.

The RECLAIM study (NCT06868212) represents a notable addition to the late-stage CSU pipeline. This US-based, multicenter, randomized, double-blind, double-dummy phase 3b study is designed to compare remibrutinib — an oral, highly selective BTK inhibitor approved by the FDA for CSU — against dupilumab, an interleukin-4 receptor-α monoclonal antibody also approved by the FDA for CSU in early 2025, in approximately 400 patients with moderate-to-severe CSU symptomatic despite second-generation H-antihistamines. Patients are randomized 1:1 to oral remibrutinib (25 mg twice daily) or subcutaneous dupilumab (600 mg loading dose; 300 mg every 2 weeks). The primary endpoint is absolute change from baseline in UAS7 at week 4, with secondary endpoints including UAS7 change at week 1, achievement of well-controlled disease (UAS7 ≤6) at weeks 2 and 4, and complete disease control (UAS7 = 0) at week 4. The study is currently recruiting.

How the EMBARQ-CSU Trials Were Designed to Address CSU

Several randomized, controlled trials have investigated therapeutic interventions in chronic spontaneous urticaria (CSU), spanning biologic agents, small-molecule inhibitors, and patient-reported outcome validation studies. The trials below represent a cross-section of phase Ib through phase IIb designs, each employing distinct endpoints to capture disease activity, symptom burden, and health-related quality of life.

Barzolvolimab's Potential to Address Key Unmet Needs in CSU

Despite meaningful advances in CSU management, substantial gaps remain in disease control for a significant proportion of patients — particularly those who fail or respond inadequately to existing standard-of-care therapies.

• Omalizumab-refractory patients represent a critical unmet population. Omalizumab achieves complete hive resolution in approximately 45% of patients and does not produce lasting remission, leaving a substantial subset inadequately controlled. Among one cohort of 338 CU patients receiving omalizumab, 30.3% were non-responders, with female sex, higher baseline UAS7, and older age associated with omalizumab failure.

• Patients failing multiple lines of therapy require novel mechanistic options. In one real-world analysis, omalizumab-refractory adults had failed an average of 5.6 ± 2.6 therapies including cyclosporine before achieving complete response with dupilumab — underscoring the depth of treatment resistance in this population and the need for agents with distinct mechanisms of action.

• Endotype-defined subpopulations remain inadequately matched to targeted therapies. Two characterized endotypes — type I autoallergic (IgE-mediated against autoantigens) and type IIb autoimmune (IgG-mediated against IgE or FcεRI) — differ in disease severity, duration, and treatment response, yet the clinical utility of corresponding biomarkers such as total IgE and IgG anti-thyroid peroxidase remains limited given the historically narrow therapeutic menu.

• Patients with isolated angioedema constitute a distinct, underserved subgroup. Approximately 10% of CSU patients present with angioedema only; those with isolated mast-cell mediated angioedema have distinct clinical and demographic features and require differentiation from bradykinin-mediated angioedema — a distinction with direct therapeutic implications that current treatment algorithms do not fully address.

• Antihistamine-refractory CSU broadly represents a phenotype with considerable clinical challenge. The therapeutic landscape is expanding to address this population through BTK inhibition (remibrutinib, now FDA-approved), IL-4/IL-13 blockade (dupilumab, FDA-approved for H1-antihistamine-refractory CSU), and c-Kit inhibition, reflecting the scale of unmet need beyond first- and second-line options.

Barzolvolimab's Phase 3 Success: A New Era for Refractory CSU

The recent positive topline results from Celldex's Phase 3 EMBARQ-CSU trials for barzolvolimab represent a pivotal moment for patients suffering from chronic spontaneous urticaria (CSU). This debilitating condition, characterized by persistent hives and angioedema, significantly impairs quality of life, and a substantial proportion of patients find little relief from current standard treatments. While H1-antihistamines are the first line, and omalizumab serves as a second-line option, many individuals remain refractory, highlighting a critical unmet need for more effective and disease-modifying therapies.

Barzolvolimab, an anti-KIT monoclonal antibody, offers a distinct therapeutic approach by targeting and depleting mast cells, which are central to the pathogenesis of CSU. This mechanism differentiates it from other approved and emerging treatments, such as anti-IgE antibodies or Bruton's tyrosine kinase inhibitors. Earlier clinical studies have consistently demonstrated barzolvolimab's ability to induce rapid and sustained symptom reduction, with a notable proportion of patients achieving complete response, even among those who had previously failed omalizumab. The positive Phase 3 outcomes reinforce this promising profile, suggesting barzolvolimab could become a crucial option for those with difficult-to-treat CSU.

However, as with any novel therapy, strategic considerations and potential risks must be carefully weighed. While generally well-tolerated, barzolvolimab's safety profile includes unique adverse events like hair color changes, neutropenia, and skin hypopigmentation, which will necessitate thorough patient education and long-term monitoring. Furthermore, while sustained efficacy has been observed, the potential for barzolvolimab to induce lasting remission after treatment cessation—a significant goal in CSU management—requires further elucidation. Entering the market in 2027, barzolvolimab will join a landscape that has already seen the introduction of other innovative therapies. Celldex will need to articulate a clear value proposition, emphasizing its unique mechanism and robust efficacy in refractory populations, to secure its place in the evolving CSU treatment paradigm and ultimately improve outcomes for patients.